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The following, from the 12th OESO World Conference: Cancers of the Esophagus, includes commentaries on the
clinicaldifferencesbetweencarcinomasarising slightlyabove, slightlybelow,andwithin thegastroesophageal junction
(GEJ); information provided by biopsies; information provided by resection specimens following neoadjuvant
therapy; histologic differences existing between carcinomas arising slightly above, slightly below, and within the
GEJ; differences provided by immunohistochemistry in these tumors; information given by endoscopic mucosal
resection specimens; the role of esophageal pyloric gland adenomas as precursors of adenocarcinomas in the region
of the cardia; the role of pancreatic metaplasia; Her2 immunoreactivity to make distinctions in the site of origin; and
intestinal metaplasia limited to the cardia as a precursor of adenocarcinoma.
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Concise summary
Clinical distinctions tend to segregate type I adeno-
carcinoma of the gastroesophageal junction (GEJ)
from types II and III. Oncologically, patients with
type III GEJ carcinomas tend to present at later
stages and appear to have worse survival following
resection than those with type I and type II. On-
cologically, patients with type III carcinomas tend
to present at later stages and appear to have worse
survival following resection than patients with type
I and type II, although this may be more dependent
on tumor stage at presentation than anatomic lo-
cation. When examining patterns of lymph node
metastases, patients with type I were found to
have involvement of posterior mediastinal parae-
sophageal lymph nodes in addition to upper ab-
dominal lymph node basins. The staging systems
for esophageal and gastric carcinomas have become
more uniform and translatable, particularly when
considering GEJ carcinomas.
The tumor morphology does not help to distin-
guish the distal esophageal adenocarcinoma (EAC)
from the adenocarcinoma of the GEJ or proximal
stomach, especially when it is of intestinal subtype.
On biopsies, the tissue available for interpretation
is often limited, as sampling is usually limited to
the tumor and distal stomach mucosa is not avail-
able. Reported features helpful in distinguishing
distal esophageal from proximal gastric columnar
mucosa are the presence of severe crypt atrophy
and disarray, especially if they are combined with
findings of diffuse incomplete intestinal metaplasia
(IM); squamous epitheliumoverlying crypts,multi-
layered epithelium, esophageal glands and/or ducts;
and presence of hybrid glands. In biopsies of the
GEJ region, although there are certainhistologic fea-
tures that canhelp pathologists determinewhether a
doi: 10.1111/nyas.12535
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particular biopsywith columnar epitheliumwas ob-
tained from the distal esophagus or the proximal
stomach, these features are only present in about
30% of cases.
For tumors that show a high degree of regres-
sion following neoadjuvant therapy, one may only
be able to identify a scarred tumor bed with su-
perficial ulceration or even re-epithelization. The
rates of significant tumor regression are higher in
EACs type I as compared to adenocarcinomas of
the GEJ (types II and III). Likewise, the probability
for the latter tumors to achieve tumor regression
is higher than in more distally located gastric can-
cers. These findings may be helpful for therapeu-
tic decisions before initiating preoperative therapy
in terms of response prediction. According to the
current definitions of the World Health Organiza-
tion (WHO) and the Union Internationale Contre´
le Cancer/American Joint Committee on Cancer
(UICC/AJCC), the presence of Barrett’s mucosa
does not refine EAC from adenocarcinoma of the
GEJ, since anatomic landmarks and not molecular
genetic origin are considered as crucial for the clas-
sification of adenocarcinomas arising in this area.
No studies formally comparing adenocarcino-
mas slightly above, at, and below the GEJ have
been published, investigating the histological dif-
ferences between intestinal-typemucosa–associated
and cardiac-typemucosa–associated adenocarcino-
mas. However, recent studies showed that EACs are
more frequently well differentiated and gland form-
ing than gastric cancers. In addition, the compari-
son of surgically resected EACs (Siewert type 1)with
GEJ adenocarcinomas (Siewert type II) showed that
all tumor types were present in both locations, but
tumors associated with IM in the esophagus showed
glandular morphology significantly more often.
There are trends of immunohistochemical differ-
entiation by location in the phenotype of adeno-
carcinoma; however, that phenotype is not specific
for location. The human embryonic esophagus is
columnar lined in early development and under-
goes squamous epithelialization in utero by a se-
ries of changes in gene expression. Therefore, im-
munohistochemistry is more sensitive and specific
for patterns of differentiation or gene expression
than for anatomical location. Barrett’s neoplastic
differentiation may be in an intestinal (goblet cell
metaplastic) or a gastric foveolar direction, the lat-
ter without goblet cell phenotype. Both foveolar
dysplasia in the esophagus and gastric adenocar-
cinomas share similar staining patterns, including
loss or aberrant expression of lethal giant larva 2
(LGL2) in foveolar dysplasia, compared to reactive
gastric mucosa. In contrast, expression of LGL2 is
also frequently lost in areas of IM. Although the
majority of esophageal and GEJ adenocarcinomas
display intestinal-like immunophenotype, cardiac-
type differentiation is definitely not limited to or
specific for adenocarcinomas arising in the GEJ or
stomach, as gastric foveolar dysplasia can be seen in
a significant subset of EACs. FindingHeliobacter py-
lori organisms by immunohistochemistry suggests
an origin of the adenocarcinoma in the stomach, be-
low the GEJ, rather than a GEJ or distal esophageal
origin.
Regardless of whether a small amount of
mucous or mixed mucous/oxyntic glands (i.e., car-
dia or cardiac-type mucosa) at the GEJ is nor-
mal, evidence shows that its length increases with
age, acid exposure, and with histologic evidence
of esophagitis and carditis. Therefore, metaplas-
tic esophageal mucosa is essentially similar to the
histology of cardiac mucosa and it can be very
difficult, if not impossible, to distinguish these
histologically in some cases. Endoscopic mucosal
resection (EMR) specimens ideally include submu-
cosal tissue and are helpful in assessing esophageal
location through identification of features such
as submucosal glands/ducts, duplicated muscularis
mucosae, squamous islands/buried columnar mu-
cosa, and palisade vessels.
To study the possible neoplastic potential of
pancreatic acinar metaplasia (PAM) at the GEJ,
the expression of c-erbB2, a receptor tyrosine ki-
nase implicated in the development of pancreatic,
esophageal, and gastric cancers, and K-ras, a tumor
oncogene expressed in over 80% of pancreatic ade-
nocarcinomas, was studied in patients with PAM
with no evidence of BE. Neither gene was expressed.
A relationship between PAM at the GEJ and gas-
troesophageal reflux disease (GERD) and H. pylori
infection in the stomach has been shown, with a po-
tential neoplastic potential. The possible expression
of c-erbB2, a receptor tyrosine kinase implicated in
the development of pancreatic, esophageal, and gas-
tric cancers, and K-ras, a tumor oncogene expressed
in over 80% of pancreatic adenocarcinomas, was
studied in patients with PAM with no evidence of
BE, but neither was expressed.
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In several studies, positivity for Her2, a trans-
membrane receptor protein belonging to the epi-
dermal growth factor receptor (EGFR) family, was
related to aggressive tumors and poor outcome. It
has been shown thatHer2 positivity is strongly asso-
ciated with the intestinal path of tumor progression
at theGEJ, rather than the cardiac type/foveolar dys-
plasia. In contrast, there were no significant differ-
ences between the groups in pathology or outcome.
The differing rates of Her2 expression between the
esophagus, GEJ, and distal stomach may all be due
to the variation in the rates of intestinal-type cancers
between the sites.
IM limited to the cardia is a particular histologi-
cal finding that is detected with variable frequency
by different series, depending on several elements,
including endoscopic techniques, location/number
of biopsies, and histological methods. Most authors
identified H. pylori infection and reflux disease as
the main factors in the onset of cardiac inflamma-
tion andhence of intestinalmetaplasia, emphasizing
the role of IM as risk factor for cancer development.
Intestinal metaplasia is a frequent finding in the car-
diac region, evenwhen endoscopy is normal and has
an important significance in the progression toward
dysplasia and cancer.
1. Are there clinical features that
distinguish between adenocarcinomas
arising slightly above, slightly below, or at
the GEJ?
Andrew C. Chang
andrwchg@umich.edu
The GEJ, also designated the gastric cardia, indi-
cates the point of transition from esophageal squa-
mous epithelium to gastric mucosa. It has become
widely accepted that a malignancy, typically an ade-
nocarcinoma, with its epicenter arising within 5 cm
proximal or distal to this site, can be classified by
the anatomic–topographic classification described
by Siewert et al.:1 type I tumors develop proximal
to the cardia and infiltrate the GEJ distally; type II
tumors are centered at the cardia; type III tumors
arise within 5 cm distal to the GEJ and extend prox-
imally. While the GEJ is defined by endoscopic and
histologic criteria, the squamocolumnar junction or
Z-line, often used as a reference point defining the
cardia, can be difficult to identify clinically, partic-
ularly in the setting of extensive IM. Clinical dis-
tinctions tend to segregate type I adenocarcinoma
of the GEJ (AEG) from types II and III AEG. Male
sex, history of GERD, presence of a hiatal hernia,
and identification of IM of the distal esophagus
(Barrett’s esophagus (BE)) are factors more com-
monly associated with type I AEG than the more
distal types II and III tumors.2,3
Oncologically, patients with type III carcinomas
tend to present at later stages and appear to have
worse survival following resection than patients
with type I and type II GEJ carcinomas,4 although
this may be more dependent on tumor stage at pre-
sentation than anatomic location. Pathologic stag-
ing reported in several contemporary surgical series
indicated that patients referred for resection ofmore
distal AEGs (i.e., types II or III) were more likely
to have increasingly advanced stage of disease with
higher grade tumors compared toproximalAEGs.4,5
The majority of patients undergoing resection for
adenocarcinomas of the GEJ were found to have
lymph node involvement,4–6 with a tendency for
more extensive lymph node involvement observed
in the distal type III AEGs.4,5
When examining patterns of lymph node
metastases, patients with type I AEGs were found
to have involvement of posterior mediastinal
paraesophageal lymph nodes in addition to upper
abdominal lymph node basins. The more distal
type II and III AEGs had markedly less involvement
of mediastinal lymph nodes, with disease residing
predominantly in the upper abdominal lymph node
basins, notably the paracardial, lesser curvature,
celiac axis, and greater curvature regions.4,6,7 With
the adoption of the seventh edition of the AJCC
and UICC staging criteria for esophageal cancer,
arising from the Worldwide Esophageal Cancer
Collaboration,8 the staging systems for esophageal
and gastric carcinomas have become more uniform
and translatable, particularly when considering
GEJ carcinomas.9,10 As the esophagus lacks a serosa,
tumor (T) staging continues to differ in terms of
transmural invasion, in which T3 gastric cancers
are defined as invading the serosa, whereas T3
esophageal cancers extend to the adventitia. In the
seventh edition AJCC/UICC TNM staging schema,
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however, criteria for lymph node (N) staging of
esophageal carcinomas focuses primarily on the
number of suspected or pathologically confirmed
metastatic lymph nodes. Anatomic location (e.g.,
celiac axis lymph node involvement previously
considered asmetastatic disease (M1a)) is no longer
considered in the nodal (N) staging schema.
2. How does the pathologist tell from
biopsies?
Genevie`ve Soucy
genevieve.soucy.chum@ssss.gouv.qc.ca
When evaluating biopsies of the GEJ region, knowl-
edge of the exact biopsy site and endoscopic im-
pression is essential. Usually, pathologists rely on
endoscopists for conveying information regarding
the anatomic site of biopsy samples. Determining
the precise site of the biopsy may be difficult for the
endoscopist, especially when the tumor obliterated
the anatomic landmarks.
Answering this question is thus very challenging
for pathologists for several reasons. First, the tu-
mor morphology does not help to distinguish distal
EAC from adenocarcinoma of the GEJ or proximal
stomach, especially when it is of intestinal subtype.
Esophageal and gastric adenocarcinomas of intesti-
nal subtypearehistologically indistinguishable, hav-
ing arisen on a background of IM.11,12 Second, on
biopsies, the tissue available for interpretation is of-
ten limited. Indeed, sampling is usually limited to
the tumor, with the objective of establishing a di-
agnosis of malignancy. Often, sampling of adjacent
mucosa or distal stomach mucosa is not available.
Based on the recognized etiologic mechanisms
that EAC is strongly associated with GERD and
BE with healthy gastric mucosa, and gastric ade-
nocarcinoma is strongly associated with H. pylori
gastritis, gastric atrophy, and IM, pathologists can
look for the presence of nontumoral mucosa to help
them identify the probable site of origin, as either
esophageal or gastric.12–15
Useful nontumoral mucosa includes adjacent or
distal gastric or esophageal mucosa. Despite the
finding of dysplasia in these biopsies, other features
have been reported to be helpful in distinguishing
distal esophageal from proximal gastric columnar
mucosa.
In biopsies of the GEJ region, differentiation of
metaplastic esophageal columnar epithelium from
normal proximal stomach (cardia), regardless of the
presence or absence of goblet cells, is often difficult
or impossible. However, few histologic features have
been reported to help locate the mucosa at the GEJ
in a setting of GERD.16
Reported features helpful in distinguishing distal
esophageal from proximal gastric columnarmucosa
are the presence of severe crypt atrophy and disar-
ray; especially if they are combined with findings of
diffuse incomplete IM, squamous epithelium over-
lying crypts (buried columnar epithelium), multi-
layered epithelium, esophageal glands and/or ducts,
and presence of hybrid glands. Unfortunately, the
presence of goblet cells, by itself, does not allow the
pathologist to determine if a biopsy is esophageal or
gastric in location.16 The coexistence of more than
four of these features was 95% sensitive and 95%
specific for predicting diagnosis of BE in the setting
of GERD, known to be associated with EAC.16
In biopsies of the GEJ region, although there are
certain histologic features that can help patholo-
gists determine whether a particular biopsy with
columnar epithelium was obtained from the distal
esophagus or the proximal stomach, these features
are only present in about 30% of cases.16
Biopsy samples from native esophageal epithe-
lium and distal stomach should be obtained dur-
ing the same procedure. Indeed, these biopsies are
quite useful, sincemostH. pylori–associated carditis
cases also show H. pylori antritis, thus favoring an
adenocarcinoma of gastric origin. In contrast, ac-
tive reflux esophagitis combined with the finding of
a normal antrum or corpus are strong evidence in
favor of GERD and adenocarcinoma of esophageal
origin.12,15,17–19
In conclusion, pathologists can help endoscopists
in identifying the site of origin of an adenocarci-
noma based on recognized etiologic mechanisms,
as long as adjacent mucosa or distal stomach mu-
cosa samples are available for interpretation. Even
with those biopsy samples, a minority of cases show
helpful features and could possibly be correctly clas-
sified according to their site of origin.
3. How does the pathologist tell from
resection specimens following
neoadjuvant therapy?
Rupert Langer
rupert.langer@pathology.unibe.ch
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Figure 1. Macroscopic examples of esophagectomy resection specimens with adenocarcinomas of the esophagus/GEJ after neo-
adjuvant chemotherapy with (A) significant regression and (B) no regression. It is hard to appreciate the original site of the tumor
in A since there now is only a scarred tumor bed visible. The tumor probably was located within the GEJ. In contrast, in B the tumor
appears quite unchanged after treatment, and one would classify this tumor as esophageal cancer just not reaching the GEJ.
Gastroesophageal adenocarcinomas show a con-
siderable variability in response to neoadjuvant
treatment.20–22 In cases of no or little regression,
the macroscopic appearance of the tumor may re-
flect the pretherapeutic conditions. In these cases,
the appreciation of the origin of the tumor and
a classification into one of the three sites of ori-
gin (esophagus, GEJ, stomach; or following the
Siewert classification: AEG I, II, III or stomach)
may be possible. In contrast, for tumors that show a
higher degree of regression, one may only be able to
identify a scarred tumor bed with superficial ulcer-
ation or even re-epithelization (Fig. 1). Under these
circumstances, it can be impossible to precisely de-
termine the localization of the initial tumor on the
basis of the macroscopic or even histologic appear-
ance of the resection specimen.
However, in the management of locally ad-
vanced gastroesophageal adenocarcinomas, which
currently consists of neoadjuvant or perioperative
treatment followed by surgery, most of the diagnos-
tically and therapeutically relevant decisions have
already been made before start of the preoperative
therapy.
The presence of the tumor is diagnosed based
on the endoscopic picture, but there is also the di-
agnostic biopsy taken from the tumor during en-
doscopy. In many cases, the determination of the
tumor site is also done based on the relation of the
tumor to landmarks such as the Z-line or the gas-
tric foldswithin this investigation. Endo-ultrasound
and other imaging diagnostics confirm the local or
disseminated extension of the tumor. The results of
these early investigations have immediate influence
on further management, such as the decision in fa-
vor or against multimodal treatment concepts. In
addition, the subsequent surgical approach will also
be determined based on this categorization.
Interestingly, the rates of significant tumor re-
gression are higher in EACs/AEG I as compared to
adenocarcinomas of the GEJ/AEG II and III.22,23
Likewise, the probability for the latter tumors to
achieve tumor regression is higher than in more
distally located gastric cancers.23 These findingsmay
be helpful for therapeutic decisions before initiat-
ing preoperative therapy in terms of response pre-
diction. There is the general observation that pa-
tients with completely regressed tumors have a very
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good clinical outcome. Tumors without significant
regression have a far worse prognosis. For tumors
with partial or subtotal regression, there may ex-
ist differences regarding the effects of the degree of
regression. Several studies show that patients with
these tumors (e.g., 1–50% residual tumor) show an
intermediate prognosis between complete respon-
ders and nonresponders.21,22 In contrast, adeno-
carcinomas of the GEJ/AEG II and III are more
similar to gastric cancer, where carcinomas with
total and subtotal regression (e.g., <10% residual
tumor) have been shown to have a significantly bet-
ter prognosis compared to partial or no regression
(i.e., >10% residual tumor).20 The classification of
tumor regression, however, is not internationally or
even nationally standardized.24 Amore detailed dis-
cussionabout the various tumor regression–grading
systems would be far beyond the borders of this
report.
At last, an interesting finding has been reported
by Theisen et al., who describe the phenomenon of
unmasking Barrett’s mucosa through neoadjuvant
chemotherapy.25 In these cases, an origin as an EAC
arising within a Barrett’s mucosa can be postulated.
However, according to the current definitions of the
WHO26 and the UICC/AJCC,27,28 the presence of
Barrett’s mucosa does not refine EAC from adeno-
carcinoma of the GEJ, since anatomic landmarks
and not molecular genetic origin are considered
as crucial for the classification of adenocarcinomas
arising in this area.
4. Adenocarcinomas slightly above,
slightly below, and within the
esophagogastric junction: are they
histologically different?
Xavier Sagaert and Gert De Hertogh
xavier.sagaert@uzleuven.be
Adenocarcinomas of the distal esophagus, GEJ, and
cardia continue to rise in incidence, especially in
the Western world. An intestinal metaplasia (BE)–
dysplasia–carcinoma sequence induced by GERD
has been well established. Barrett’s metaplasia is
a predominant risk factor for the development
of adenocarcinoma (30- to 50-fold increased risk
in comparison to the general public). However,
a significant number of adenocarcinomas in the
vicinity of the GEJ are seen in the background of
gastric/cardiac-type mucosa without IM. This has
led to a couple of studies investigating, among other
parameters, the histological differences between
intestinal-typemucosa–associated and cardiac-type
mucosa–associated adenocarcinomas.
Older studies demonstrated the presence of some
clinicopathological differences between esophageal,
cardiac, and distal gastric cancers. In 1984, Kalish
et al. found that 23 esophageal and 49 cardiac ade-
nocarcinomas (all surgically resected) were almost
identical with regard to growth pattern (expansile
vs. infiltrative), tumor grade, and tumor stage.29
This was more or less confirmed by Wang et al.
in 1986, when comparing 12 esophageal, 9 GEJ,
and 26 surgically resected cardiac adenocarcinomas;
while no significant differences were found between
esophageal and cardiac adenocarcinomas in terms
of tumor grade, they did biologically behave dif-
ferently from infracardial gastric adenocarcinomas:
the presence of signet ring cells was less frequently
observed, and signet ring cell differentiationwas less
extensive when present.22 In 1993, Heidl et al. came
to the same conclusion by comparing a large se-
ries of 66 esophageal, 359 cardiac, and 1288 infrac-
ardial adenocarcinomas: no significant differences
between esophageal and cardiac adenocarcinomas
could be found for Borrmann’s, WHO, Ming’s, and
Laure´n’s classifications.30
Two more recent studies showed that EACs are
more frequently well differentiated and gland form-
ing than gastric cancers. In 2006, 215 esophageal,
108 cardiac, and 184 gastric adenocarcinomas (tu-
mor location defined by the Siewert criteria) were
histologically graded, staged, and typed according to
the Carneiro’s, WHO, and Laure´n’s classifications
by Sarbia.31 It was found that esophageal cancers
displayed the same histological spectrum as cardiac
and gastric cancer; however, the relative propor-
tion of differentiated, gland-forming carcinomas
was significantly more frequent in the esophagus
than in the cardia or in the stomach. Remarkably, in
this particular study, among EACs, Lauren’s classi-
fication, Carneiro’s classification, tumor grade, and
lymphatic vessel invasion, but not theWHOclassifi-
cation, were histological predictors of postoperative
survival. In 2011, Demicco et al. clinicopathologi-
cally compared 51 surgically resected EACs (Siewert
type I)with 106GEJ adenocarcinomas (Siewert type
II).14 It was found that all tumor types (low- and
high-grade glandular type, signet ring cell, muci-
nous, medullary, adenosquamous) were present in
216 Ann. N.Y. Acad. Sci. 1325 (2014) 211–225 C© 2014 New York Academy of Sciences.
Al-Haddad et al. Adenocarcinoma at the gastroesophageal junction
both locations, but tumors associatedwith intestinal
(Barrett’s)metaplasia in the esophagus showedglan-
dular morphology significantly more often (even
after correcting for tumor diameter).
Despite the fact that the results arising from older
and more recent studies investigating the histologi-
cal features in esophageal, GEJ, and cardiac adeno-
carcinomas are somewhat conflicting, the number
of studies analyzing the histological differences re-
mains limited, and so far, no studies formally com-
paring adenocarcinomas slightly above, at, and be-
low the GEJ have been published.
5. Are there immunohistochemical
differences between carcinomas arising
slightly above, slightly below, or at the
GEJ?
Melissa P. Upton
mupton@uw.edu
If immunohistochemical differences are detected,
are they dependent on anatomic site or on embry-
ologic origin? Do they reflect differences in etiology,
such as H. pylori versus reflux? Are they markers of
differentiation, such as intestinal versus gastric fove-
olar differentiation, rather than location?
First, how is location defined? Most studies use
the Siewert classification, which defines type I as
having an epicenter 1–5 cm proximal to the GEJ;
type II with epicenter 2–5 cm distal to the GEJ,
(subcardial, invading frombelow); and type III with
epicenter located between 1 cm proximal and 2 cm
distal to the GEJ (true GEJ tumors).2 Although the
location can be defined after esophagogastrectomy,
the preoperative endoscopic localization of the GEJ
remains problematic. In one study, gastroenterol-
ogists (n = 80) were asked to identify the prox-
imal gastric folds from photomicrographs of the
GEJ taken from 30 patients with BE. The  coeffi-
cient for identification of the proximal gastric folds
was only 0.35, even after training.32 It is unlikely
that in vivo endoscopic GEJ identification could
be more reliable; hence, site designation of endo-
scopic biopsies is not precise, and studies based
on endoscopic location are confounded by this
limitation.
How is location above, below, or at the GEJ re-
lated to embryological origin? In the early embryo,
the stomodeum gives rise to the foregut. Structures
that arise from the foregut include the esophagus,
stomach, duodenum, liver, pancreas, and respira-
tory system. As foregut derivatives, they may share
certain immunohistochemical markers. This ex-
plains the fact that carcinomas arising in this broad
region can expressmarkers associatedwith differen-
tiation into other foregut-derived tissues. Thus, we
can find EACs that have Hepar-1 cytoplasmic ex-
pression, TTF-1 nuclear expression, and/or CDX-2
expression. The human embryonic esophagus is
columnar lined in early development and under-
goes squamous epithelialization in utero through
a series of changes in gene expression. Therefore,
immunohistochemistry is more sensitive and spe-
cific for patterns of differentiation or gene expres-
sion than for anatomical location. And subtle dif-
ferences in location over the 10-cm region that
spans the GEJ are unlikely to result in specific im-
munohistochemical differences among neoplasms
related to whether they arise above or below the
GEJ.
Animal models provide additional evidence that
the GEJ is a transition zone populated by migrating
cell populations, depending on physiological set-
ting and gene expression. The p63 knockout mouse
model illustrates the role of migratory cell popula-
tions toGEJ epithelialization andpossible neoplasia.
In stratified squamous epithelia, p63 is required for
stem cell regeneration, but it is not required for lin-
eage differentiation in nonsquamous directions. In
the p63 knockoutmousemodel, the number of p63-
expressing squamous stem cells is reduced. If the an-
imals are subjected to acid reflux that damages the
distal esophagus, residual embryonic cells of gastric
origin migrate into the distal esophagus, leading
to replacement of the squamous lining by colum-
nar lining of gastric type (i.e., columnar metapla-
sia). Similarly, altered expression of p63 in humans
might lead to incomplete squamous epithelializa-
tion during fetal life or aberrant re-epithelialization
after injury, such as acid reflux.14,33,34
Barrett’s neoplastic differentiation may also be
in an intestinal (goblet cell metaplastic) or a gastric
foveolar direction, the latter without goblet cell
phenotype. In a Cleveland Clinic study of 3698
biopsies with BE, 1779 biopsies from 461 patients
had dysplasia. One hundred and sixty (8.9%) of
the biopsies from 44 (9.5%) patients had foveolar
dysplasia only, including 74 low-grade and 86
high-grade biopsies, and these were investigated
immunohistochemically. In this study, MUC2
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Table 1. Immunohistochemical characteristics of neoplasms, compared according to their background mucosa
Intestinal-type background Cardiac-type background
More commonly low grade with nuclear -catenin expression (P< 0.0080)
Less likely to exhibit EGFR amplification (P< 0.0051)
Less commonly express nuclear -catenin (P< 0.0080)
More commonly exhibit EGFR amplification (P< 0.0051)
More frequently express CDX2 (P = 0.020) Neoplasms are negative for MUC2, CDX2, CD10
Membranous CD10 and cytoplasmic MUC2 in 10% of neoplastic cells
Negative for MUC5AC and MUC6 Positive for MUC5AC and MUC6
There were also cases with mixed IHC phenotype and null cases without IHC expression of these markers in both Siewert locations
expression was not seen in normal foveolar zone or
in foveolar dysplasia; however, Barrett’s dysplasia
with a goblet cell (intestinalized) component
was positive for MUC2. Intestinalized dysplasia
also expresses MUC2. In addition, both foveolar
dysplasia in the esophagus and gastric adenocar-
cinomas share similar staining patterns, including
loss or aberrant expression of lethal giant larva 2
(LGL2) in foveolar dysplasia, compared to re-
active gastric mucosa. In contrast, expression
of LGL2 was also frequently lost in areas of
IM.35
Exploring this dichotomy of gastric versus in-
testinal lines of differentiation in neoplasms in
this region, 157 esophagectomy specimens of BE-
associated and GEJ adenocarcinomas were com-
pared, and their anatomic locations classified using
the Siewert system. The neoplasms included only
distal esophageal and GEJ adenocarcinomas, and
the background mucosa was characterized as in-
testinal versus cardiac type and assessed for dyspla-
sia. Table 1 summarizes comparative immunohis-
tochemical expression profiles of the carcinomas by
background mucosa: intestinal versus cardiac type.
The Siewert location was significantly associated
with the presence or absence of adjacent IM (P =
0.0009). The prevalence of IM was 86% in Siewert
type I and 60% in Siewert type II adenocarcinomas.
CDX2 expression was seen in 53% of Siewert type
I adenocarcinomas and 38% of Siewert type II ade-
nocarcinomas. Also of note, there were cases that
exhibited mixed or null phenotypes.36 These find-
ings provide additional evidence that although the
majority of EACs andGEJ adenocarcinomas display
intestinal-like immunophenotype, cardiac-type dif-
ferentiation is definitely not limited to or specific for
adenocarcinomas arising in the GEJ or stomach, as
gastric foveolar dysplasia can be seen in a significant
subset of EACs.
Finally, does the neoplastic immunophenotype
reflect etiology, such as H. pylori infection versus
reflux? Seropositivity forHelicobacter is strongly as-
sociated with noncardiac gastric adenocarcinoma
(adjusted OR = 7.9) and inversely associated with
cardiac gastric adenocarcinoma (adjusted OR =
0.31), and H. pylori infection is not associated with
neoplasia in BE. Therefore, findingH. pylori organ-
isms by hematoxylin and eosin (H&E) or immuno-
histochemistry suggests an origin of the adenocar-
cinoma in the stomach, below the GEJ, rather than
a GEJ or distal esophageal origin.
In summary, there are trends of immunohis-
tochemical differentiation by location in pheno-
type of adenocarcinoma; however, that phenotype
is not specific for location. The finding of associated
H. pylori infection favors gastric origin. Other than
H. pylori detection, immunohistochemical expres-
sion patterns of adenocarcinomas around the GEJ
appear to be more associated with histological phe-
notype or lines of differentiation than with anatom-
ical site of origin or location.
6. How does the pathologist tell from
EMR specimens?
Andrea Grin
grina@smh.ca
In order to answer this question, we first need
to know the normal histology above, at, and just
below the GEJ. While the histologic features of the
esophagus just above the GEJ and the gastric fundic
mucosa just below the GEJ are well established, nor-
mal histology at the GEJ is a matter of debate. One
line of thinking is that the normal GEJ is composed
of a direct transition from squamous to oxyntic
mucosa and that any so-called cardiac (formed
of mucous cells only) or oxyntocardiac (mixture
of parietal and mucous) mucosa is metaplastic
218 Ann. N.Y. Acad. Sci. 1325 (2014) 211–225 C© 2014 New York Academy of Sciences.
Al-Haddad et al. Adenocarcinoma at the gastroesophageal junction
secondary to damage from GER. This viewpoint is
supported by thework of Chandrasoma et al., which
includes a prospective autopsy study showing a
direct transition from squamous to oxyntic mucosa
(with no cardiac mucosa) in the majority of cases.37
The opposing view is that the cardia is, in fact,
a normal structure but is very short. A pediatric
autopsy series (mean age 6.3 years) demonstrated
cardiac mucosa (composed of mucous cells only)
in all cases with a mean length of 1.8 mm.38
Zhou et al.39 found either mucous or mixed
mucous/oxyntic mucosa at the GEJ in all fetal and
pediatric autopsies examined, with the exception of
one case. Similarly, biopsies of the GEJ of pediatric
patients (mean age 13.0 years) demonstrated pure
mucous glands within 1 mm of the squamous
mucosa in 81% of patients, and a direct transi-
tion from squamous to oxyntic mucosa was not
seen.40
Regardless of whether a small amount of mu-
cous ormixedmucous/oxyntic glands (i.e., cardia or
cardiac-typemucosa) at theGEJ is normal, evidence
shows that its length increases with age, acid expo-
sure, andwith histologic evidence of esophagitis and
carditis.40,41 Therefore, metaplastic esophageal mu-
cosa (i.e., BE) is essentially similar to the histology
of cardiac mucosa and it can be very difficult, if
not impossible, to distinguish these histologically in
some cases.
As opposed to biopsies, EMR specimens are larger
and ideally include submucosal tissue. These differ-
ences are helpful in assessing esophageal location.
Features most useful in confirming esophageal lo-
cation in an EMR specimen are (1) the presence of
esophageal submucosal glands and/or ducts, (2) du-
plicated muscularis mucosae, and (3) squamous is-
lands or buried columnar mucosa with IM. A newly
described but less well-appreciated feature, palisade
vessels, is also gaining recognition.
Submucosal glands and ducts
Themost reliable feature and one shown to have the
highest level of interobserver agreement is the pres-
ence of submucosal glands and/or ducts. Submu-
cosal glands are present throughout the length of the
esophagus but are more numerous both proximally
and distally. Submucosal glands develop during the
fourth month of gestation from ciliated colum-
nar mucosa; therefore, their presence can be ac-
cepted as histologic evidence of esophageal location.
Submucosal glands and/or ducts can be seen in ap-
proximately 20–30% of EMR specimens.42
Duplication of the muscularis mucosae
Duplication of themuscularis mucosae is clearly as-
sociated with BE and is thought to be part of the
morphologic changes of Barrett’s metaplasia, which
includes not only epithelial metaplasia but also
stromal changes. Duplication has not been iden-
tified within the stomach nor in esophagectomy
specimens without BE.43 While a duplicated mus-
cularis mucosa can be identified in approximately
90% of esophagectomy specimens with BE,7 the de-
tection rate is somewhat lower in EMR specimens
(65–70%)44 and the extent of duplication varies and
can be focally present.44,45 In one study, extensive
duplication was seen in 38% of specimens, moder-
ate in 33%, and minimal in 29%.44 Another EMR
study showed minimal (<10%) or absent duplica-
tion in the majority (54%) of cases.45
Squamous islands or buried columnar
mucosa with IM
Since squamous mucosa is found in the esophagus
and not in the stomach, the presence of squamous
islands within glandular mucosa and buried colum-
nar mucosa with IM supports an esophageal loca-
tion. Squamous islands within an area of columnar
mucosa have been shown to be a diagnostic feature
of BE, and these are often associated with an un-
derlying submucosal gland or duct.46 In EMR spec-
imens, squamous islands are seen in approximately
20% of specimens.
Palisade vessels
Japanese gastroenterologists use the lower limit of
palisade vessels to define the GEJ, but these are
not well appreciated histologically. A study by Aida
et al.42 showed that veins >100 um within the mu-
cosa (above the true muscularis mucosae) were
specific for esophageal origin in EMR speci-
mens. Venous size within the lower esophagus
and within BE was significantly larger than in the
mid-esophagus, gastric cardia, and fundus. The au-
thors conclude that palisade vessels are a specific his-
tologic marker of tissue originating from the lower
esophagus.
Conclusion
The normal histology at the GEJ is a matter of
debate and the cardia (if it exists) and metaplas-
tic esophageal mucosa show histologic overlap,
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causing difficulty for the pathologist. EMR speci-
mens have the advantage of increased samplingwith
the inclusion of the submucosa. This may allow for
identification of features associated with esophageal
location such as submucosal glands/ducts, du-
plicated muscularis mucosae, and squamous is-
lands/buried columnar mucosa. Palisade vessels are
a newly recognized feature. In the absence of one
of these features, the pathologist cannot be certain
if the EMR is from the esophagus, and in these
instances, correlating with endoscopic/clinical im-
pression is required.
7. Are esophageal pyloric adenomas
possible candidates for a precursor lesion
of adenocarcinoma arising from cardia?
What evidence do we have?
Monika Tripathi, Andrea Grin,
Catherine J. Streutker, and Michael Vieth
monika.tripathi@doctors.org.uk
Over the last two decades, with the rising incidence
of EAC, there has been a parallel rise in the inci-
dence of GEJ and gastric cardia adenocarcinoma
(GCA).47,48 In contrast to EAC, the GCAs do not
have a strong association with IM nor BE. The pos-
sible candidates for precursor lesions for GCAs in-
clude IM, H. pylori and carditis, foveolar dysplasia,
and gastric-type pyloric adenomas.47
Pyloric gland adenoma (PGA) is a rare neoplasm
with distinct histomorphology and is frequently as-
sociated with transition from dysplasia to carci-
noma. PGAs were first classified as a rare gastric
tumor in 1990.49 They occur predominantly in the
elderly and have a slight female predilection. A
significant proportion of these are associated with
autoimmune gastritis. On histomorphology, they
consist of tightly packed pyloric-type glands lined
by a single layer of cuboidal to columnar mucus-
secreting cells containing pale eosinophilic cyto-
plasm with lack of apical mucin cap, in contrast
to gastric foveolar epithelium. They have a charac-
teristic immunophenotype, showing expression of
MUC5AC in the deeper parts and MUC6 in the
apical surface epithelial layer and are negative for
CDX2, CD10, and MUC2.50
About 85% are located in the stomach, pre-
dominantly in the fundus (64%), with a small
minority (7.9%) within the cardia.51 The 15% of
the extragastric sites include gall bladder, pancreatic
duct, duodenum, bile duct, uterine cervix, rectum,
and two cases within the esophagus.52 The first case
within the esophagus was reported in by Kushima
et al. in 2005.53 It was a small 3 × 2 mm polyp aris-
ing in a background of BE. Immunophenotype was
positive for MUC6 and MUC5AC and negative for
CD10 andMUC2.Complete genomic hybridization
analyses of this lesion showed losses on 2p24–
25.2, 2q14.1–ter, 5q31.3–32, 6q23–24, 8q23–24.2,
11q22.3–24, and 18q21.1–22. Interestingly, most of
the molecular studies on GCA have shown losses of
both 5q and 18q inmore than 50% of cases, indicat-
ing definite association between these two entities.54
Following this, one more case of PGA was re-
portedwithin the lower esophagus; this was a 1.5 cm
bulging tumor growing beneath the squamous
epithelium and was associated with conventional-
type low-grade dysplasia, indicating its unstable/
premalignant potential.55 But no cases of adeno-
carcinoma arising in esophageal PGA have yet
have been reported in the literature. In contrast,
different studies have documented about 30%
transition of gastric PGAs to well-differentiated
adenocarcinoma.56
Retrospective review of 37 cases of GCAs diag-
nosed at our center showed only 35.2% associ-
ation with background IM and only three cases
with H. pylori infection, but no case of PGA has
been reported at this site. Due to its rarity, there
is not enough evidence supporting its malignant
transition at the esophageal site (only two cases
reported in the indexed literature), although the
cases reported so far show definite molecular as-
sociation between the esophageal PGAs and the
GCA. One of the reasons for scant clinical data
might be frequent underdiagnosis and unawareness
of these lesions at the extragastric sites, and they are
likely not as rare as they are described in published
literature.
8. Can pancreatic metaplasia be a
possible precursor of adenocarcinoma at
the GEJ?
Sahar Al-Haddad
Al-HaddadS@smh.ca
Metaplasia is the transformation of one type of
mature tissue to another type. PAM at the GEJ
is the transformation of gastric-type mucosa to
pancreatic-type mucosa. It was first reported by
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Doglioni et al. in 1993.57 The reported prevalence
ranges between 14% and 24%.58,59
Some authors have argued for a congenital origin
for pancreatic metaplasia, whereas others suggested
an acquired etiology. Those in favor of an acquired
mechanismhave shown a relationship between pan-
creatic metaplasia and GERD and also H. pylori in-
fection in the stomach.60,61 Oneof themost convinc-
ing reports of a possible congenital origin for PAM
wasmade in 1999 by Luque-Barona, who studied 67
consecutive infantile autopsies and found two cases
of PAM in the stomach, one in a 3-month-old infant
who suffered bilateral renal dysplasia and complex
polymalformative syndrome and the second in a 5-
month-old infant with extrahepatic biliary atresia
who died from sepsis after surgery.62
Johansson et al. found an overall prevalence of
PAM of 18%, with 10% being below the GEJ, 6%
above the GEJ, and 2% at the level of the GEJ. Those
above the GEJ were significantly associated with
H. pylori and GERD.61
In two studies of a variant of gastric adenocar-
cinoma with pancreatic acinar-like differentiation
arising in the proximal stomach and invading the
esophagus, none of the 43 cases in the first study or
the case reported in the second study showed pan-
creatic acinar metaplasia in adjacent benign gastric
tissue.63,64
K-ras is a tumor oncogene expressed in over 80%
of pancreatic adenocarcinomas. c-erbB2 is a recep-
tor tyrosine kinase implicated in the development
of pancreatic, esophageal, and gastric cancers. To
study any possible neoplastic potential for PAM,
Polkowski et al. investigated the possible expression
of c-erbB2 and K-ras in patients with PAM with no
evidence of BE, and neither was expressed.60
While future studies may produce different
findings, the current evidence shows no indication
of a neoplastic potential for pancreatic acinar
metaplasia.
9. Is there reason to make a distinction
about site of origin with respect to Her2
immunoreactivity?
Catherine J. Streutker
StreutkerC@smh.ca
The Her2 receptor is a transmembrane receptor
protein belonging to the EGFR family. The Her2
protein is involved in a number of cell functions,
including growth, differentiation, proliferation, and
survival. It is present at low levels on normal gastric
epithelial cells, but in a proportion of tumors, it is
overexpressed.65 The Trastuzumab for Gastric Can-
cer (ToGA) trial, demonstrating responsiveness of
gastric and GEJ adenocarcinomas to traztuzumab,
showed significant differences in the rate of Her2
positivity between GEJ (33%) versus distal stom-
ach (21%) adenocarcinomas, most often in moder-
ately to well-differentiated intestinal-type tumors.66
Scoring of Her2 for these tumors is significantly
different from that used in breast carcinomas (i.e.,
incomplete membrane staining is allowed and het-
erogeneity is a frequent finding).67 Her2 positivity
in several studies was related to aggressive tumors
and poor outcome, but this has not been replicated
in all studies.68,69
Comparing adenocarcinomas of the esophagus
to those in the GEJ and stomach has shown some
variability. Yoon et al. looked at 713 tumors; 17%
were Her2+ overall. In EAC, Her2 positivity was
21%, compared to 15% for those at the GEJ or
gastric cardia.70 In their study, Her2 positivity cor-
related with lower tumor grade, less invasiveness,
and fewer lymph node metastases. As the presence
of Her2-amplified tumors also correlated with the
presence of adjacent Barrett’s mucosa, the authors
concluded that Her2 positivity is strongly associ-
ated with the intestinal path of tumor progression
at the GEJ, rather than the cardiac type/foveolar
dysplasia. In contrast, Phillips et al. found only 15%
of esophageal primary adenocarcinoma and 28%
of GEJ primary adenocarcinoma were Her2+, and
they found that there were no significant differences
between the groups in pathology or outcome.71
Table 2. The SMH experience of Her2 expression in 658
cases of adenocarcinoma of the distal esophagus, GEJ,
cardia, and distal stomach. Overall, 22% of cases were
positive for Her2
Site
Distal
esophagus GEJ Cardia Stomach
# of cases 79 157 16 406 (approxi-
mately 40%
had no site
specified)
% Her2+ 26% 35% 12.5% 18%
% diffuse/
mixed
8.8% 12% 31% 36%
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St. Michael’s Hospital is part of the gastric cancer
Her2 testing network for Ontario, Canada. Analysis
of tested cases was done to evaluate for the rate of
Her2 positivity at, above, and below the GEJ, where
noted on the requisitions from incoming cases.
(Table 2) This appears to show differences between
the different sites; however, this may be entirely due
to the rate of diffuse gastric cancer. This type of
tumor is rare in the esophagus and is only very
rarely positive for Her2 overexpression; the differ-
ing rates of Her2 expression between the esophagus,
GEJ, and distal stomach may all be due to the vari-
ation in the rates of intestinal-type cancers between
the sites. Further studies are needed to determine
if there are significant biologic differences between
these tumors with respect to Her2 positivity and
response to trastuzumab.
10. IM limited to the cardia
Vincenzo Villanacci and Marianna Salemme
villanac@alice.it
The correct definition of the cardiac region is still
controversial. In general, it is considered as a care-
fully localized anatomical region present in healthy
individuals, and in this sense Odze wrote “the
level at which the esophagus ends and the stomach
begins.”72 Nevertheless, the experience of Chandra-
soma on autopsy37 denied this theory. In his au-
topsy analysis, 30% of 72 patients did not have any
cardiac mucosa, while all 71 patients with reflux
disease had cardiac mucosa, suggesting that car-
diac mucosa is not a normal structure but is an
abnormal mucosa that results from the metaplastic
transformation of the squamous epithelium dam-
aged by the reflux. Against this definition, there are
the experiences of Kilgore and Glickman: the first,
analyzing 30 pediatric autopsies, identified the pres-
ence of cardiac mucosa in all cases (ranging from
1 to 4 mm in length), while the latter studied 74
pediatric patients, in which he identified the dif-
fuse presence of pure mucous glands or mixed mu-
cous/oxyntic glands, typical histological hallmarks
of cardiacmucosa.38,40 On thebasis of thesedifferent
interpretations, we consider the cardia as a definite
area of the stomach that is present both in normal
anatomy and in pathological conditions. IM limited
to the cardia is aparticularhistological finding that is
detected with variable frequency (ranging from 0%
to36%)bydifferent series, dependingon several ele-
ments, including endoscopic techniques (e.g., mag-
nification, acetic acid, vital dye), location/number
of biopsies, and histological methods (e.g., Alcian
blue; Fig. 2). In particular, it is important to high-
light the role of a correct biopsy sampling, based
on an adequate number of biopsies above (Barrett’s
area) and below (cardiac region) the Z-line, separat-
ing biopsies from these different areas into specific
containers. In the literature, several causes of car-
diac IM have been studied, such as age, smoking,
and overweight;73 however, most authors identified
H. pylori infection and reflux disease as the main
factors in the onset of cardiac inflammation and
hence of IM (Table 3).74 This concept has been also
remarked by Goldblum,75 according to which the
significance of IM near the GEJ in an individual
patient should be evaluated in the context of en-
doscopic findings, histological and serologic data
for H. pylori infection, and information obtained
from biopsies of the distal stomach. The role of IM
in the cardiac region has consequently been inves-
tigated. In two different series, Cameron et al.76,77
Figure 2. Intestinalmetaplasia in the cardiac region. (A)Hematoxylin–eosin, originalmagnification 10×. (B) Alcian–Pas staining,
original magnification 40×.
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Table 3. Concurrent presence of Helicobacter pylori infection/reflux disease at the time of the diagnosis and the
development of dysplasia/cancer during the follow-up period
IM in the cardia
Low-grade
dysplasia
Low- and
high-grade
dysplasia
Intestinal-type
cancer
Diffuse-type
cancer
Mixed-type
cancer
H. pylori infection 0 0 7 2 2
Reflux disease 1 2 12 3 0
demonstrated that in both small and large adeno-
carcinomas of the cardia, IM was present with a
high frequency (in 86% and 42% of cases, respec-
tively), emphasizing the role of IM as an important
risk factor for cancer development. In our experi-
ence, from 2000 to 2012, we found the histological
features of IM limited to the cardia in 133 patients
undergoing cardiac biopsies; among these, 30 pa-
tients had concurrent H. pylori infection, while the
remaining cases had a concomitant reflux disease.
During the follow-up period, three cases developed
dysplasia and 26 developed cancer. The histolog-
ical analysis of cases with cancer revealed in 19
patients (73%) the presence of an intestinal-type
cancer. Taken together, the results of our experi-
ence emphasize the concept that IM is a frequent
lesion in the cardiac region, even when endoscopy
is normal and has an important preneoplastic sig-
nificance in the progression toward dysplasia and
cancer.
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